GoodRx Holdings Inc.

08/12/2026 | Press release | Distributed by Public on 08/12/2026 15:25

Initial Statement of Beneficial Ownership (Form 3)

FORM 3
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0104
Estimated average burden hours per response... 0.5
(Print or Type Responses)
1. Name and Address of Reporting Person *
Fengler Justin
2. Date of Event Requiring Statement (Month/Day/Year)
08/06/2026
3. Issuer Name and Ticker or Trading Symbol
GoodRx Holdings, Inc. [GDRX]
(Last) (First) (Middle)
C/O GOODRX HOLDINGS, INC., 2701 OLYMPIC BOULEVARD
4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
_____ Director _____ 10% Owner
__X__ Officer (give title below) _____ Other (specify below)
See Remarks
5. If Amendment, Date Original Filed (Month/Day/Year)
(Street)
SANTA MONICA, CA 90404
6. Individual or Joint/Group Filing (Check Applicable Line)
_X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
(City) (State) (Zip)
Table I - Non-Derivative Securities Beneficially Owned
1.Title of Security
(Instr. 4)
2. Amount of Securities Beneficially Owned
(Instr. 4)
3. Ownership Form: Direct (D) or Indirect (I)
(Instr. 5)
4. Nature of Indirect Beneficial Ownership
(Instr. 5)
Class A Common Stock 23,651 D
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. SEC 1473 (7-02)
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security
(Instr. 4)
2. Date Exercisable and Expiration Date
(Month/Day/Year)
3. Title and Amount of Securities Underlying Derivative Security
(Instr. 4)
4. Conversion or Exercise Price of Derivative Security 5. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 5)
6. Nature of Indirect Beneficial Ownership
(Instr. 5)
Date Exercisable Expiration Date Title Amount or Number of Shares
Restricted Stock Unit (1) (1) Class A Common Stock 10,149 (2) D
Restricted Stock Unit (3) (3) Class A Common Stock 25,695 (2) D
Restricted Stock Unit (4) (4) Class A Common Stock 16,341 (2) D
Restricted Stock Unit (5) (5) Class A Common Stock 70,311 (2) D
Restricted Stock Unit (6) (6) Class A Common Stock 76,703 (2) D
Restricted Stock Unit (7) (7) Class A Common Stock 9,775 (2) D
Restricted Stock Unit (8) (8) Class A Common Stock 324,900 (2) D
Stock Option (Right to Buy) (9) 05/22/2028 Class A Common Stock 575 $5.18 D
Stock Option (Right to Buy) (10) 01/30/2030 Class A Common Stock 219,375 $5.9405 D
Stock Option (Right to Buy) (11) 12/20/2031 Class A Common Stock 64,324 $33.69 D
Stock Option (Right to Buy) (12) 09/21/2032 Class A Common Stock 264,137 $5.45 D
Stock Option (Right to Buy) (13) 05/23/2033 Class A Common Stock 146,575 $5.22 D
Stock Option (Right to Buy) (14) 03/05/2034 Class A Common Stock 48,776 $7.61 D
Stock Option (Right to Buy) (15) 03/04/2035 Class A Common Stock 163,126 $4.67 D
Stock Option (Right to Buy) (16) 09/03/2035 Class A Common Stock 17,622 $4.29 D

Reporting Owners

Reporting Owner Name / Address Relationships
Director 10% Owner Officer Other
Fengler Justin
C/O GOODRX HOLDINGS, INC.
2701 OLYMPIC BOULEVARD
SANTA MONICA, CA 90404
See Remarks

Signatures

/s/ Gracye Cheng, Attorney-in-Fact for Justin Fengler 08/12/2026
**Signature of Reporting Person Date

Explanation of Responses:

* If the form is filed by more than one reporting person, see Instruction 5(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
(1) This restricted stock units award vests with respect to 1/16 of the award in quarterly installments on November 15, 2022 and on each quarterly anniversary thereafter, subject to the Reporting Person's continued service through each applicable vesting date.
(2) Each restricted stock unit represents a contingent right to receive one share of Class A common stock.
(3) This restricted stock units award vests with respect to 1/16 of the award in quarterly installments on August 15, 2023 and on each quarterly anniversary thereafter, subject to the Reporting Person's continued service through each applicable vesting date.
(4) This restricted stock units award vests with respect to 1/16 of the award in quarterly installments on June 15, 2024 and on each quarterly anniversary thereafter, subject to the Reporting Person's continued service through each applicable vesting date.
(5) This restricted stock units award vests with respect to 1/16 of the award in quarterly installments on May 15, 2025 and on each quarterly anniversary thereafter, subject to the Reporting Person's continued service through each applicable vesting date.
(6) This restricted stock units award vests with respect to 1/8 of the award in quarterly installments on May 15, 2025 and on each quarterly anniversary thereafter, subject to the Reporting Person's continued service through each applicable vesting date.
(7) This restricted stock units award vests with respect to 1/16 of the award in quarterly installments on December 15, 2025 and on each quarterly anniversary thereafter, subject to the Reporting Person's continued service through each applicable vesting date.
(8) This restricted stock units award vests with respect to 1/12 of the award in quarterly installments on April 15, 2026 and on each quarterly anniversary thereafter, subject to the Reporting Person's continued service through each applicable vesting date.
(9) This option fully vested on May 1, 2022.
(10) This option fully vested on July 1, 2023.
(11) This option fully vested on October 15, 2025.
(12) This option vests and became exercisable with respect to 1/16 of the total number of shares underlying the option in quarterly installments on November 15, 2022 and on each quarterly anniversary thereafter, subject to the Reporting Person's continued service through each applicable vesting date.
(13) This option vests and became exercisable with respect to 1/16 of the total number of shares underlying the option in quarterly installments on August 15, 2023 and on each quarterly anniversary thereafter, subject to the Reporting Person's continued service through each applicable vesting date.
(14) This option vests and became exercisable with respect to 1/16 of the total number of shares underlying the option in quarterly installments on June 15, 2024 and on each quarterly anniversary thereafter, subject to the Reporting Person's continued service through each applicable vesting date.
(15) This option vests and became exercisable with respect to 1/16 of the total number of shares underlying the option in quarterly installments on May 15, 2025 and on each quarterly anniversary thereafter, subject to the Reporting Person's continued service through each applicable vesting date.
(16) This option vests and became exercisable with respect to 1/16 of the total number of shares underlying the option in quarterly installments on December 15, 2025 and on each quarterly anniversary thereafter, subject to the Reporting Person's continued service through each applicable vesting date.

Remarks:
Chief Financial Officer and Chief Strategy & Operations Officer
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, See Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.
GoodRx Holdings Inc. published this content on August 12, 2026, and is solely responsible for the information contained herein. Distributed via EDGAR on August 12, 2026 at 21:25 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]